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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: :   Mitochondrial disorders can originate from mutations in one of many nuclear genes
controlling the organelle function or in the mitochondrial genome (mitochondrial DNA
(mtDNA)). The large numbers of potential culprit genes, together with the little guidance offered
by most clinical phenotypes as to which gene may be causative, are a great challenge for the
molecular diagnosis of these disorders.
M Me et th ho od ds s: :   We developed a novel targeted resequencing assay for mitochondrial disorders relying on
microarray-based hybrid capture coupled to next-generation sequencing. Specifically, we subjected
the entire mtDNA genome and the exons and intron-exon boundary regions of 362 known or
candidate causative nuclear genes to targeted capture and resequencing. We here provide proof-of-
concept data by testing one HapMap DNA sample and two positive control samples.
R Re es su ul lt ts s: :    Over 94% of the targeted regions were captured and sequenced with appropriate
coverage and quality, allowing reliable variant calling. Pathogenic mutations blindly tested in
patients’ samples were 100% concordant with previous Sanger sequencing results: a known
mutation in Pyruvate dehydrogenase alpha 1 subunit (PDHA1), a novel splicing and a known
coding mutation in Hydroxyacyl-CoA dehydrogenase alpha subunit (HADHA) were correctly
identified. Of the additional variants recognized, 90 to 94% were present in dbSNP while 6 to
10% represented new alterations. The novel nonsynonymous variants were all in heterozygote
state and mostly predicted to be benign. The depth of sequencing coverage of mtDNA was
extremely high, suggesting that it may be feasible to detect pathogenic mtDNA mutations
confounded by low level heteroplasmy. Only one sequencing lane of an eight lane flow cell was
utilized for each sample, indicating that a cost-effective clinical test can be achieved.
C Co on nc cl lu us si io on ns s: :   Our study indicates that the use of next generation sequencing technology holds
great promise as a tool for screening mitochondrial disorders. The availability of a comprehensive
molecular diagnostic tool will increase the capacity for early and rapid identification of
mitochondrial disorders. In addition, the proposed approach has the potential to identify new
mutations in candidate genes, expanding and redefining the spectrum of causative genes
responsible for mitochondrial disorders.
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Mitochondrial disorders are the most common group of
metabolic disorders, with an estimated prevalence of 1 in
5,000 [1]. Mitochondrial disorders may present with any
symptom, in any organ, at any age and with any mode of
inheritance [2]. These often devastating disorders are
clinically characterized by multi-system involvement with
primarily progressive neurologic disease and myopathy,
including both skeletal and cardiac muscle. The variability in
clinical presentation and underlying causative mutations
make the diagnosis very challenging, involving extensive
clinical and specialized laboratory evaluation [3]. However,
no reliable diagnostic screening or biomarker is available that
is both sensitive and specific in all cases of mitochondrial
disorders [4]. In current clinical practice, the diagnosis of
mitochondrial disease relies heavily on identifying deficient
activity of one or more of the mitochondrial respiratory chain
enzymes, but in many cases the enzyme activity is found to be
only moderately decreased or even normal, which makes the
interpretation very difficult. Additionally, there are intrinsic
problems in the biochemical characterization of mitochon-
drial disorders, such as variability in tissue manifestation,
difficulty in establishing realistic normal reference ranges,
inability of enzyme assays to detect some functional defects,
variations in assay protocols, no uniform or standardized
guidelines, and lack of widely accepted diagnostic criteria and
a quality assurance scheme [5]. For these reasons, some
patients may remain undiagnosed and even die of untreated
disease. Early and definitive diagnosis is crucial for permit-
ting appropriate management and accurate counseling [3].
Thus, a new simplified and reliable approach for the diag-
nosis of mitochondrial disorders with better accuracy and
precision has been strongly advocated.
Mitochondria are cellular organelles with numerous essential
functions, such as production of energy, metabolism of amino
acids, fatty acids, and cofactors, and cell signaling. Their
biogenesis and function is under the genetic control of
mitochondrial DNA (mtDNA) and nuclear DNA. The number
of mitochondrial proteins encoded by nuclear genes is
estimated to be around 1,500 [6], constituting 99% of mito-
chondrial proteins [7]. mtDNA contains 37 genes encoding 13
respiratory chain subunits, 2 rRNAs and 22 tRNAs [8].
Because of this dual genetic control, mitochondrial disorders
can originate from mutations in either mtDNA or nuclear
genes that encode the organelle proteins [8].
Mutations have been found in approximately 170 nuclear
genes in patients with mitochondrial disorders [6,8,9].
However, many nuclear genes causing disease are still un-
known [8]. It is expected that most mitochondrial disorders
are caused by mutations in nuclear genes. The nuclear genes
encode the subunits of the complexes involved in oxidative
phosphorylation and relative assembly factors, proteins
controlling the synthesis and stability of mtDNA, mitochon-
dria transcription and translation, biogenesis, metabolism,
and signaling. While substantial progress has been made in
recent years in identifying nuclear genes that are mutated in
mitochondrial disorders, the key clinical challenge lies in
determining which one of hundreds of genes is responsible
for the disease in any given patient. Comprehensive
sequencing of all nuclear genes known to be involved in
mitochondrial disease would be cost-prohibitive and time
consuming using traditional DNA sequencing technology.
Not surprisingly, clinical tests are available for only a
limited number of nuclear genes for a few conditions in
which the causative genes can be predicted by the clinical
phenotypes [8].
Pathogenic mutations in mtDNA are found in at least one in
5,000 affected individuals [1] and appear to be very common
in the general population (>1 in 200 live births) even though
these mutations show different penetrance during the life-
time of the carriers. Many of these mutations are primarily
responsible for adult-onset mitochondrial disorders [1].
Mutations in nuclear genes are likely the major cause of
mitochondrial disease particularly in pediatric cases [3].
Nevertheless, the pediatric prevalence of mtDNA mutations
may have been underestimated because mtDNA testing is
typically performed by targeted mutation analysis. This
strategy cannot identify mutations beyond those targeted
[10]. While mtDNA (16,569 bp) could easily be sequenced by
traditional Sanger methods, this technology is inadequate to
detect some mtDNA mutations that occur in a small fraction
of the total mtDNA molecules. Indeed, mutated molecules of
mtDNA coexist with normal mtDNA (heteroplasmy) and can
be below the limit of detection of Sanger sequencing,
especially in DNA extracted from blood [11].
Within the last few years, next-generation sequencing has
been tested for whole genome or targeted resequencing with
promising results. The new platforms allow sequencing
hundreds of genes in parallel and detection of mutations or
alterations with a dramatically reduced cost. Over the coming
years, next-generation sequencing is highly anticipated to
transition from basic research applications into clinical
diagnostics [12-14]. One such opportunity is the rapid
identification of mutations in diseases that can be caused by
one of several genes, as with mitochondrial disorders.
Despite the fact that whole genome or exome sequencing is
now possible, it is still desirable to limit the analysis to genes
responsible for a certain condition for both cost benefit and
time saved for analysis and interpretation. Given that most
pathogenic mutations are typically located in coding regions
or at intron-exon boundaries, and that it is not practical to
use PCR to enrich a large number of exons, several
methodologies have been developed to enrich exons of target
genes as a preliminary step to next-generation sequencing
[15-20]. Compared with whole genome/exome sequencing,
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sequence coverage over the areas of interest.
Here, we propose to develop a comprehensive clinical diag-
nostic tool based on sequencing the entire mtDNA genome,
and the exons of previously implicated and candidate
nuclear genes (Table 1) using sequence capture technology
coupled to next-generation sequencing.
M Me et th ho od ds s
Positive control patient samples were obtained as anonymous
samples from Seattle Children’s Hospital; these were leftover
specimens after routine standard clinical testing. Mutations
in these samples were previously identified by clinical tests
using traditional sequencing. Patient 1 was Caucasian and
Patient 2 was of Caucasian-Native American origin. Human
DNA from one HapMap individual was obtained from Coriell
Repositories (NA18517, Yoruba ancestry). We used 10 µg of
DNA per individual for these studies.
Custom programmable arrays (Agilent Technologies Inc.)
were designed with 60-mer oligonucleotide probes comple-
mentary to the sequences to be captured. The target
consisted of the entire mtDNA genome and coding sequen-
ces within >3,500 exons of 362 nuclear genes for proteins
involved in mitochondrial function, for an aggregate target
size of approximately 0.6 Mb (Table 1) excluding repetitive
regions. The Consensus CDS (CCDS) database was utilized
to obtain the exon coordinates for probe design. Due to
discrepancies between identifiers used by our group and
CCDS or because CCDS is not comprehensive, a small
number of genes were inadvertently excluded from the array
design process. These included, for example, Polymerase
gamma 1 (POLG1), a nuclear gene involved in mitochondrial
disorders [21] (annotated as POLG in CCDS), and highlights
the importance of careful review in the design process.
As there are approximately 244,000 programmable oligos
on the custom arrays used here, the targeted sequences were
‘tiled’ at a very high density (that is, 40 probes per 100-bp
interval; probe sequences are available upon request). To
construct an in vitro shotgun sequencing library, genomic
DNA was sheared by nebulization and universal adaptor
oligonucleotides were ligated and then amplified using the
Illumina protocol [22]. After this step, in order to enrich for
the specific target exons and mtDNA, the amplified shotgun
libraries were hybridized to the capture array as described in
[23]. After washing to remove unhybridized material, cap-
tured molecules were recovered by heat-based elution and
subjected to PCR amplification. The target-enriched shotgun
libraries were quantified (NanoDrop Products, Wilmington,
DE, USA), and then subjected to deep sequencing on an
Illumina Genome Analyzer, GAII. One lane of the flow cell
was used for each sample. Read-lengths of up to 36 bp were
obtained with per-base accuracies on the order of 99%. The
sequence reads were aligned to the human reference
genome, first using the standard Illumina package (ELAND).
After removal of all but one of the reads mapping with
identical coordinates and orientation (potential PCR dupli-
cates), the remaining reads were remapped using the MAQ
software package [24]. Consensus calls for variant identifi-
cation were also carried with MAQ.
In order to assess the significance of new variants found in
the study, we analyzed the non-synonymous single nucleo-
tide substitutions with PolyPhen (Polymorphism Pheno-
typing), a tool that predicts the possible impact of an amino
acid substitution on the structure and function of a human
protein using physical and comparative considerations [25].
R Re es su ul lt ts s
D De ep pt th h   o of f   c co ov ve er ra ag ge e   a ac cr ro os ss s   t ta ar rg ge et te ed d   r re eg gi io on ns s
A single lane of an Illumina flow cell was used for each
sample, producing 356 Mb, 297 Mb, and 333 Mb for the
HapMap, patient 1 and patient 2 samples, respectively, that
mapped to the human genome with the Illumina ELAND
software (36 bp, single-end reads; Table 2). Of these, 17%,
35% and 30% mapped to the approximately 0.6 Mb of
targeted regions in the nuclear genome, and 37%, 20% and
27% mapped to the 16.6-kb mitochondrial genome.
Although mtDNA was represented on the capture array at an
equivalent density to nuclear genes, its high copy number is
likely responsible for its significantly greater degree of
enrichment. After removal of potential PCR duplicates and
remapping with MAQ [24], mean coverage of targeted
nuclear bases was 37×, 51× and 51× for the three samples.
Coverage of ≥8× and a consensus quality score ≥20 was
observed for 96%, 94% and 94% of target bases in the
nuclear genome. Because of variable coverage or mappa-
bility issues with short reads, a small fraction of targeted
bases (4 to 6%) were not covered sufficiently to variant call.
Because sample complexity was clearly not limiting for reads
mapping to the mtDNA, all reads mapping with MAQ were
considered (that is, without removing potential PCR
duplicates). Considering only high confidence placements
and base qualities (those with both a MAQ mapping score of
at least 20 and a MAQ base call quality score of at least 20),
mean coverage of the 16,569-bp mitochondrial genome was
5,001×, 2,936×, and 4,236× for the three samples.
M Mu ut ta at ti io on ns s   a an nd d   n ne ew w   v va ar ri ia an nt ts s   o of f   u un nk kn no ow wn n   s si ig gn ni if fi ic ca an nc ce e
The known mutations and novel non-synonymous variants
identified in the study are listed in Table 3. Mutations
identified in the two patient samples corresponded to those
previously detected by Sanger sequencing. Patient 1 is a male
hemizygote for the common mutation R263G in the X-
linked alpha subunit of the E1 enzyme (encoded by PDHA1)
of the Pyruvate dehydrogenase complex (49 reads covered
this region and all contained the variant). This nuclear-
http://genomemedicine.com/content/1/10/100 Genome Medicine 2009, Volume 1, Issue 10, Article 100 Vasta et al. 100.3
Genome Medicine 2009, 1 1: :100http://genomemedicine.com/content/1/10/100 Genome Medicine 2009, Volume 1, Issue 10, Article 100 Vasta et al. 100.4
Genome Medicine 2009, 1 1: :100
T Ta ab bl le e   1 1
G Ge en ne es s   t ta ar rg ge et te ed d   f fo or r   c ca ap pt tu ur re e   a an nd d   s se eq qu ue en nc ci in ng g
mtDNA maintenance, 
OXPHOS assembly  Transcription/  mitochondria 
OXPHOS subunits factors Enzymes translation  Carriers biogenesis/ dynamics
K Kn no ow wn n   g ge en ne es s   f fo or r   m mi it to oc ch ho on nd dr ri ia al l   d di is so or rd de er rs s
COX4I2, COX6B1,  ATPAF2, BCS1L,  ABCB7, ACAT1,  ATXN7, DARS2,  DNAJC19, SLC25A13,  c10orf2, DGUOK, 
NDUFA1, NDUFA2,  C20orf7, COX10,  APTX, ASS1,  GFM1, LRPPRC,  SLC25A15, SLC25A19,  DNM1L, ETFA, ETFB, 
NDUFA11, NDUFS1,  COX15,  BCKDHA, BCKDHB,  MRPS16, MRPS22,  SLC25A20, SLC25A22,  ETFDH, HSPD1, 
NDUFS2, NDUFS3,  NDUFAF1NDUFAF3,  CABC1, COQ9,  PUS1, RARS2,  SLC25A3, SLC25A4,  MFN2, MPV17, OPA1, 
NDUFS4, NDUFS6,  NDUFAF4, SCO1,  CYCS, DBT, DLAT,  TSFM, TUFM SLC3A1, TIMM8A PINK1, POLG2, 
NDUFS7, NDUFS8,  SCO2, SURF1 DLD, ETHE1, FH,  RRM2B, SPG7, 
NDUFV1, NDUFV2,  FXN, GFER, HADH,  SUCLA2, SUCLG1, 
SDHA, SDHB,  HADHA, HADHB,  TK2, TYMP, WFS1
SDHC, SDHD,  HMGCL, HMGCS2, 
UQCRB, UQCRQ MCCC2, OXCT1, PC, 
PCK2, PDHA1, PDHB, 
PDHX, PDSS1, PDSS2, 
PPM1B, PPM2C, 
PREPL, TAZ
C Ca an nd di id da at te e   g ge en ne es s   f fo or r   m mi it to oc ch ho on nd dr ri ia al l   d di is so or rd de er rs s
ACOT7, AMACR,  ATPAF1, COX11,  COQ10B, COQ3,  AARS2, CARS2, FARS2,  GRPEL1, HSPA9,  HSPE1, MFN1
ATP5A1, ATP5B,  COX17, COX18,  COQ4, COQ5,  IARS2, KARS, LARS2,  PAM16, SAMM50, 
ATP5C1, ATP5D,  COX19, ECSIT COQ6, COQ7,  MARS2, MRPL1,  SLC25A1, SLC25A10, 
ATP5E, ATP5F1,  PDK1, PDK2,  MRPL10, MRPL11,  SLC25A11, SLC25A12, 
ATP5G1, ATP5G2,  PDK3, PDK4, PDP2,  MRPL12, MRPL13,  SLC25A14, SLC25A16, 
ATP5G3, ATP5H,  PDPR MRPL14, MRPL15,  SLC25A17, SLC25A18, 
ATP5I, ATP5J,  MRPL16, MRPL17,  SLC25A2, SLC25A21, 
ATP5J2, ATP5O,  MRPL18, MRPL19,  SLC25A23, SLC25A24, 
ATP5S, ATPIF1,  MRPL2, MRPL20,  SLC25A25, SLC25A26, 
BCL2L13, C10orf65,  MRPL21, MRPL22,  SLC25A29, SLC25A30, 
C14orf2, COX4I1,  MRPL23, MRPL24,  SLC25A31, SLC25A32, 
COX5A, COX5B,  MRPL27, MRPL28,  SLC25A33, SLC25A34, 
COX6A1, COX6A2,  MRPL3, MRPL30,  SLC25A35, SLC25A36, 
COX6C, COX7A1,  MRPL32, MRPL33,  SLC25A38, SLC25A39, 
COX7A2, COX7B,  MRPL34, MRPL35,  SLC25A40, SLC25A42, 
COX7B2, COX7C,  MRPL36, MRPL37,  SLC25A43, SLC25A44, 
COX8A, COX8C,  MRPL38, MRPL39,  SLC25A45, SLC25A46, 
CYC1, DCI,  MRPL4, MRPL40,  SLC25A5, SLC25A6, 
FOXRED1, GAD1,  MRPL41, MRPL42,  TIMM10, TIMM13, 
GBAS, GNPAT,  MRPL43, MRPL44,  TIMM17A, TIMM17B, 
GPAM, HPDL, IVD,  MRPL45, MRPL46,  TIMM22, TIMM23, 
MGST3, MRRF,  MRPL47, MRPL49,  TIMM44, TIMM50, 
NDUFA10, NDUFA12,  MRPL50, MRPL51,  TIMM8B, TIMM9, 
NDUFA13, NDUFA3,  MRPL52, MRPL53,  TOMM20, TOMM22, 
NDUFA4, NDUFA5,  MRPL54, MRPL55,  TOMM34, TOMM40, 
NDUFA6, NDUFA8,  MRPL9, MRPS10,  TOMM40L, TOMM7, 
NDUFA9, NDUFAB1,  MRPS11, MRPS12,  TOMM70A, UCP1, 
NDUFB1, NDUFB10,  MRPS14, MRPS15,  UCP2, UCP3, VDAC1, 
NDUFB11, NDUFB2,  MRPS17, MRPS18A,  VDAC2, VDAC3
NDUFB3, NDUFB4,  MRPS18B, MRPS18C, 
NDUFB5, NDUFB6,  MRPS2, MRPS21, 
NDUFB7, NDUFB8,  MRPS23, MRPS24, 
NDUFB9, NDUFC1,  MRPS25, MRPS26, 
NDUFC2, NDUFS5,  MRPS27, MRPS28, 
NDUFV3, NIPSNAP1,  MRPS29, MRPS30, 
NIPSNAP3A, NIPSNAP3B,  MRPS31, MRPS33, 
NPL, PAH, PHYH,  MRPS34, MRPS35, 
PNPT1, PRO1853,  MRPS36, MRPS5, MRPS6, 
RNMTL1, TMEM22,  MRPS7, MRPS9, MTG1, 
UQCR, UQCRC1,  NARS2, NRF1, PARS2, 
UQCRC2, UQCRFS1,  RSPH9, SARS2, TARS2, 
UQCRH, USMG5 TFAM, TFB1M, TFB2M, 
WARS2, YARS2encoded mitochondrial matrix enzyme complex provides the
primary link between glycolysis and the tricarboxylic acid
cycle by catalyzing the irreversible conversion of pyruvate
into acetyl-CoA. The mutations in patient 2 affected the
alpha subunit of the mitochondrial trifunctional protein
Hydroxyacyl-CoA dehydrogenase (encoded by HADHA),
also called long-chain hydroxyacyl-CoA dehydrogenase
(LCHAD).  LCHAD deficiency (OMIM 609016) is a mito-
chondrial autosomal recessive disorder characterized by
early-onset cardiomyopathy, hypoglycemia, neuropathy,
pigmentary retinopathy, and sudden death due to the defect
in the beta-oxidation of fatty acids. Patient 2 is a compound
heterozygote for a novel mutation affecting the G nucleotide
of the conserved splicing acceptor site [26] at the 5’ end of
exon 5 (35 reads, 18 with the mutation), and the common
mutation E510Q [27] (64 reads, 39 with the mutation).
In the three samples, approximately 90% (301 over 336 total
variants identified), 94% (297 over 315), and 93% (291 over
314) of the identified variants were previously documented in
dbSNP (version 129). A limited number of novel variants were
non-synonymous and all in the heterozygote state. Many of
the same variants were also identified in unrelated samples
from a human exome study that included 12 subjects (Table 3)
[23]. The new variants were analyzed with PolyPhen [25],
searched in Cardiff’s Human Gene Mutation Database [28],
aligned in search of homologous regions by BLAST [29] and
compared to orthologues with the Conserved Domain
Database [30] (Table 3). Only one variant was predicted as
probably damaging. This was a cysteine to glycine substitution
in the protein encoded by MTG1, a conserved protein required
for assembly of the large ribosomal subunit [31]. However, an
alignment to orthologues showed that non-polar neutral
residues can be substituted at this position. In particular, a
glycine occupies this position, within a conserved region, in a
ribosomal biogenesis GTPase from Mycoplasma pneumoniae
[GenBank:NP_110345.1], indicating that the observed substi-
tution may be tolerated. Nonetheless, it would be interesting
to test the ability of the variant protein to rescue the
respiratory deficient yeast mtg1 mutant [31], as this may be
one of the as yet unidentified causative genes that are
present in the population. A novel non-conservative substi-
tution from asparagine to glycine was observed in the
penultimate amino acid of Frataxin, a protein involved in the
regulation of mitochondrial iron content mutated in one
form of Frederich Ataxia (OMIM 229300). This was
predicted as a possibly damaging variant. However, this
position is not conserved between orthologues and is
glycine in mouse, indicating that this terminal amino acid
may not be functionally important [32]. Two samples
shared a conservative substitution from arginine to serine
in Prolyl endopeptidase-like (PREPL), a novel oligo-
peptidase involved in hypotonia-cystinuria syndrome [33].
This was predicted to be possibly damaging; however, in a
search of orthologue proteins, a protease from Rickettsia
conorii [GenBank:NP_360014] was shown to contain serine
at the same position within a shared conserved motif. An
arginine to glutamine substitution in the protein encoded by
MRPS5, a member of the small mitochondrial ribosome
subunit, was predicted to be possibly damaging. This
position is conserved but not invariant in MRPS5
orthologues. Phosphoenolpyruvate carboxykinase 2 (PCK2)
presented a substitution at the donor splice site of intron 9
from the consensus GT to the non-canonical GC. Since GC is
observed in some intron donor sites, it is hard to predict if
this variant may affect splicing. A missense variant of the
first codon of the beta subunit of the mitochondrial
trifunctional protein Hydroxyacyl-CoA dehydrogenase
(HADHB) could not be confirmed with traditional Sanger
sequencing. This is an homozygote duplication of CTA in the
first exon of the HADHB gene that we saw previously in
normal samples ([GenBank:NM_000183.2] c.8_10dupCTA)
and was also detected in [23]. We then visually inspected the
reads and were able to recognize that the variant was
actually sequenced properly, while the artifactual variant
had been called by MAQ. We believe these artifacts can be
reduced with an improved recognition of indel variants
using 76-bp reads and utilizing other analysis tools, such as
’cross-match’, as exemplified in [23].
Interestingly, both the HapMap individual and patient 2 are
carriers for two identical mutations in recessive genes. The
first is a novel stop mutation in the gene DBT, encoding the
Dihydrolipoyl transacylase subunit (E2) of Branched-chain
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T Ta ab bl le e   2 2
S Sp pe ec ci if fi ic ci it ty y   a an nd d   d de ep pt th h   o of f   c co ov ve er ra ag ge e   f fo or r   t ta ar rg ge et te ed d   r re eg gi io on ns s
Percentage of  Percentage of  Mean fold-  Mean fold-
reads mapping to  reads mapping to  coverage of  coverage of  Percentage of 
Sequence targeted  nuclear  mtDNA  targeted  mtDNA  called  variants 
Sample output genes genome nuclear genes genome in dbSNP 129
HapMap 356 Mb 17 37 37× 5,001× 90
Patient 1 297 Mb 35 20 51× 2,936× 94
Patient 2 333 Mb 30 27 51× 4,236× 93http://genomemedicine.com/content/1/10/100 Genome Medicine 2009, Volume 1, Issue 10, Article 100 Vasta et al. 100.6
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T Ta ab bl le e   3 3
N Ne ew w   v va ar ri ia an nt ts s   a an nd d   m mu ut ta at ti io on ns s   i id de en nt ti if fi ie ed d   i in n   t th he e   s sa am mp pl le es s
Alterations OMIM number Prediction Notes
H Ha ap pM Ma ap p   s sa am mp pl le e
P PR RE EP PL L 606407 Possibly  Same variant present in orthologue Protease II [NP_360014]. PREPL was 
[Genbank:NM_006036.3]:  damaging* reported as one of the genes deleted in the homozygous 2p21 deletion 
c.1769A>C (p.Asn590Ser) het syndrome 
F FX XN N 229300 Possibly The  FXN gene encodes the protein Frataxin, which is involved in mitochondrial 
[Genbank:NM_000144.3]:  damaging*  iron metabolism. Clinical significance is unclear as this amino acid is not 
c.626A>G (p.Asp209Gly) het conserved in orthologues. Gly in mouse orthologue
D DB BT T 248600 The DBT gene encodes the E2 component of branched-chain alpha-keto acid 
[Genbank:NM_001918.2]:  dehydrogenase complex involved in the catabolism of the branched-chain amino 
c.725C>A (p.Ser242Stop) het acids. Nonsense mutation at position 224 in single nucleotide polymorphism 
rs74103423
M MR RP PL L4 46 6 Benign* Component of the large subunit of the mitochondrial ribosome. No mutations 
[Genbank:NM_022163.3]:  were reported in patients
c.107C>T (p.Ala36Val) het
S SL LC C2 25 5A A4 45 5 Benign* Variant in pseudogene [NW_923184.1]. Thr in mouse orthologue
[Genbank:NM_182556.2]: 
c.299T>C (p.Met100Thr) het
S SL LC C2 25 5A A3 3 610773 Benign* Mitochondrial phosphate carrier deficiency can be caused by mutation in the 
[Genbank:NM_213611.2]:  SLC25A3 gene, which encodes the mitochondrial phosphate carrier. Variant in 
c.1066A>C (p.Lys356Gln) het pseudogene [NT_009775.16]. Gln in Armadillo orthologue
P PA AH H 261600 Benign* PAH encodes Phenylalanine hydroxylase. This variant was reported as a
[Genbank:NM_000277.1]:  potential mutation for phenylketonuria [34]
c.500A>G (p.Asn167Ser) het
P Pa at ti ie en nt t   1 1   s sa am mp pl le e: :   p py yr ru uv va at te e   d de eh hy yd dr ro og ge en na as se e   d de ef fi ic ci ie en nc cy y
P PD DH HA A1 1 312170 M Mu ut ta at ti io on n† † The PDHA1 gene encodes the alpha subunit of Pyruvate decarboxylase, the first 
[Genbank:NM_000284]:  of three enzymes in the Pyruvate dehydrogenase complex
c.787C>G (p.Arg263Gly) 
M MT TG G1 1 Probably  MTG1 encodes a conserved protein required for assembly of the large  
[Genbank:NM_138384.2]:  damaging ribosomal subunit. Glycine in this position in ribosomal biogenesis GTPase of 
c.151T>G (p.Cys51Gly) het Mycoplasma pneumoniae [NP_110345]. No mutations were reported in patients
S SL LC C2 25 5A A5 5 Possibly  ADP/ATP translocase. Variant in pseudogene [NW_923184.1] 
[Genbank:NM_001152.3]: damaging
c.811T>C (p.Phe271Leu) het
M MR RP PL L9 9 Benign* Component of the large subunit of the mitochondrial ribosome. No mutations 
[Genbank:NM_031420.2]:  have been reported in patients
c.637A>G (p.Ile213Val) het
H HA AD DH HB B 609016 Benign* The HADHB gene encodes the beta subunit of the mitochondrial trifunctional 
[Genbank:NM_000183.2]: protein involved in mitochondrial beta-oxidation of fatty acids. This variant was 
c.3G>T (p.Met1Ile) het not confirmed by Sanger sequencing. Visual inspection of the reads confirmed 
the Sanger sequencing results
P PC CK K2 2 261650 PCK2 encodes Phosphoenolpyruvate carboxykinase 2. Mutations in this gene 
[Genbank:NM_004563.2]:  cause phosphoenolpyruvate carboxykinase deficiency
c.1470+2T>C het
P Pa at ti ie en nt t   2 2   s sa am mp pl le e: :   l lo on ng g   c ch ha ai in n   a ac cy yl l- -C Co oA A   d de eh hy yd dr ro og ge en na as se e   d de ef fi ic ci ie en nc cy y
H HA AD DH HA A 609016 M Mu ut ta at ti io on n† † The HADHA gene encodes the alpha subunit of the mitochondrial trifunctional 
[Genbank:NM_000182.4]:  protein involved in mitochondrial beta-oxidation of fatty acids 
c.1528G>C (p.Glu510Gln) het
H HA AD DH HA A 609016 M Mu ut ta at ti io on n† †
[Genbank:NM_000182.4]: 
c.315-1G>A het
Continued overleafalpha-keto acid dehydrogenase complex, one of the genes
causing maple syrup urine disease (OMIM 248600); the
second is a known mutation in Phenylalanine hydroxylase
(PAH) [34], the gene mutated in phenylketonuria (OMIM
261600). This specific variant was observed in one case with
benign persistent hyperphenylananinemia, although not
conclusively identified as pathogenic [34]. This variant was
also identified in normal samples in a human exome study
that included 12 subjects, indicating that it is likely a poly-
morphism [23]. While phenylketonuria is not a mitochon-
drial disorder, PAH was included in the list of candidate
genes relying on an approach that uses shared evolutionary
history to identify functionally related components of complex
I [35]. Additional variants were predicted to be benign.
Alignment to the human genome by BLAST identified some of
the same variants in pseudogenes; therefore, it is possible that
these highly homologous regions were captured as well.
In the HapMap individual and patients 1 and 2 known
polymorphisms were also recognized at 41, 28, and 24
positions, respectively, in mtDNA in homoplasmic state
(defined here as >95% of high-quality bases corresponding
to a non-reference allele at a given position in a given
individual). Our criteria for identifying sites of potential
heteroplasmy in the mitochondrial genome included >200×
coverage of the position with high-quality bases, and the
observation of more than one allele at >5% frequency (that
is, at least ten high-quality observations of the alternative
allele). Six candidate heteroplasmic polymorphisms were
identified in the three samples. However, after manual
curation, variants in low complexity regions or regions with
genome homology could not be confidently called. For
example, one variant, m.4716C>A (AC_000021, Revised
Cambridge Reference Sequence for mtDNA), was observed in
all samples and accounted for 6%, 15% and 21% of the reads
in the HapMap and patient 1 and 2 samples, respectively.
This is a non-synonymous variant in the gene ND2, which
encodes the NADH dehydrogenase 2 subunit of complex I.
This C>A transversion would cause the missense mutation
Gln83Lys in ND2, predicted to be probably damaging by
PolyPhen. While it has been shown that heteroplasmic
pathogenic mtDNA mutations are common in the general
population [1], this is likely not a significant variation given
the patient’s clinical diagnosis. A likely explanation is that a
highly homologous pseudogene on chromosome 1
([GenBank:LOC100131754]; similar to NADH dehydrogenase
subunit 2) is also being captured to some extent, and
incorrect mapping of some percentage of reads results in the
observation of apparent heteroplasmy in all samples. By con-
trast, a heteroplasmic variant in which we had more confi-
dence, m.16175A>G, was observed in the patient 2 sample,
with approximately 50% of reads corresponding to each
variant. This position is A in a non-coding region of the
reference mtDNA sequence while it is G in a deposited
mtDNA sequence (AF346989). We confirmed by Sanger
sequencing the presence of this heteroplasmic variant.
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T Ta ab bl le e   3 3
C Co on nt ti in nu ue ed d
Alterations OMIM number Prediction Notes
P Pa at ti ie en nt t   2 2   s sa am mp pl le e: :   l lo on ng g   c ch ha ai in n   a ac cy yl l- -C Co oA A   d de eh hy yd dr ro og ge en na as se e   d de ef fi ic ci ie en nc cy y   ( (c co on nt ti in nu ue ed d) )
S SL LC C2 25 5A A1 15 5 238970 Benign Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome is caused by 
[Genbank:NM_014252.3]:  mutations in the SLC25A15 gene, which encodes the mitochondrial ornithine 
c.269A>T (p.Gln90Leu) het transporter. Variant in pseudogene [NW_923184.1] 
M MR RP PS S5 5 Possibly  Component of the small subunit of the mitochondrial ribosome. No mutations 
[Genbank:NM_031902.3]:  damaging were reported in patients. This position is conserved but not invariant in MRPS5
c.851G>A (p.Arg284Gln) het orthologues
P PR RE EP PL L 606407 Possibly  Notes as above
[Genbank:NM_006036.3]: damaging*
c.1769A>C (p.Asn590Ser) het
D DB BT T 248600 This variant is present in the HapMap sample above
[Genbank:NM_001918.2]: 
c.725C>A (p.Ser242Stop) het
P PA AH H 261600 Benign* Notes as above
[Genbank:NM_000277.1]: 
c.500A>G (p.Asn167Ser) het
M MR RP PL L9 9 Benign* Notes as above
[Genbank:NM_031420.2]: 
c.637A>G (p.Ile213Val) het
GenBank accession numbers are given in square brackets. Polyphen predictions are not available for stop variants or splice site variants. *Variant also
seen in normal samples in [23]. †Mutations previously identified in positive controls. Het, heterozygote.D Di is sc cu us ss si io on n
We have developed an assay to streamline the molecular
diagnosis of mitochondrial disorders by simultaneous
sequencing of the entire mtDNA genome and the exons of
362 nuclear genes for targeted mitochondrial proteins. The
current list of targeted genes includes 104 nuclear genes for
which the causative mutations were previously found in
various symptomatic patients [6,8,21,36-40], the entire
mtDNA genome, and 258 additional nuclear genes poten-
tially involved in mitochondrial disorders but that were
never reported in patients due to either no attempts to
sequence them or lack of clinically available testing (Table 1).
The known/candidate genes include all of the structural
components of oxidative phosphorylation complexes, as well
as other mitochondrial proteins of the following functional
groups: respiratory complex assembly factors, transcription
and translation factors, enzymes, and carrier proteins. Some
of the genes causing secondary inhibition of the mitochon-
drial respiratory chain are also included in this panel. One
criterion for inclusion in the list of candidate genes was that
members of each group had already been implicated in
mitochondrial disease. Some candidate genes were recently
reported as components of mitochondrial respiratory com-
plexes by proteomics [6,35] or identified as candidate genes
by integrative genomics [6,41]. Since we first compiled the
list of putative genes, three were identified as causing mito-
chondrial disease in patients (C20orf7, CoQ9 and NDUFAF3
[41-43]). This encourages us to interrogate candidate genes
in suspected patients with unknown molecular defects.
In order to build a cost-effective but comprehensive diag-
nostic approach, we performed multiplex capture of the
regions of interest using patients’ DNA followed by
sequencing with an Illumina Genome Analyzer. Considering
that the majority of pathogenic mutations are in coding
regions or at intron-exon boundaries, we restricted capture
and sequencing to these subsequences in genes of interest.
The total target size is approximately 0.6 Mb for the exons of
the 362 nuclear genes and 16.6 Kb for the entire mtDNA
genome. This strategy allows circumventing the high costs of
PCR and conventional sequencing for a large number of
targets, while maintaining high sensitivity and specificity for
detection of potentially pathogenic variants. Coverage of ≥8×
and a consensus quality score ≥20, which in our experience
allows reliable variant calling [23], was observed for 96%,
94% and 94% of target bases in the nuclear genome in the
HapMap, patient 1 and 2 samples, respectively. Normal and
patient DNA samples with known pathogenic mutations
were tested blindly. All known mutations in two different
genes in the patients’ DNA samples were identified correctly.
The common mutation R263G in the X-linked gene PDHA1,
which encodes a subunit of the Pyruvate dehydrogenase
complex, was identified in the patient 1 sample. The
observed mutation in PDHA1 has been described in patients
with Leigh syndrome [44], a condition characterized by
extensive genetic heterogeneity, since it can be due to
mutations in several genes (OMIM 256000) and is thus a
paradigm for the utility of the proposed assay. The
mutations in the patient 2 sample affect HADHA, also called
long-chain hydroxyacyl-CoA dehydrogenase (LCHAD).
Patient 2 is a compound heterozygote of a novel mutation
affecting the G nucleotide of the conserved splicing acceptor
site [26] at the 5’ end of exon 5 and the common mutation
E510Q [27]. Several polymorphisms in mtDNA were identi-
fied and the depth of sequencing coverage was extremely
high, indicating that it will be feasible to detect pathogenic
mtDNA mutations in the presence of low level heteroplasmy
undetectable with Sanger sequencing. While validation with
a larger panel of positive controls for nuclear and mtDNA
mutations is needed, this approach appears highly promis-
ing since approximately 95% of the targeted regions of 362
nuclear genes were sequenced and the results for known
mutations were 100% concordant. The high sensitivity of
this method as well as the power to identify gene-disease
relationships has been well demonstrated in a whole exome
sequencing study [23].
While the mutations in the analyzed samples were known at
the offset, this study exemplifies the necessity to interpret
and validate with traditional sequencing potentially patho-
genic new variants identified in patients with unknown
molecular defects. However, our results indicate that the
number of new variants is not as high as we anticipated.
Indeed, of the variants identified in the samples, 90 to 94%
were present in dbSNP while 6 to 10% represented new
variations. Most of the non-synonymous new variants were
predicted to be benign when analyzed with PolyPhen. Only
few of the variants were predicted as possibly or probably
damaging. However, a review of the literature or alignment
to orthologues indicates that these may be tolerated changes.
Moreover, after filtering these variants with the new variants
identified in normal samples by exome sequencing [45], only
three variants in the patient 1 sample and two variants in the
patient 2 sample would have required careful interpretation.
In summary, we anticipate that with more data on individual
genomes/exomes, the panel of polymorphisms present in
the population will grow, thus reducing the need to interpret
new variants and the extent of traditional sequencing to
confirm the variants. While the use of prediction tools and
analysis of the literature on the affected proteins can provide
a relatively easy way to assess the significance of the new
variants, integrated bioinformatic support seems very impor-
tant for the successful implementation of next-generation
sequencing in the clinical arena.
A variable range of coverage was achieved across the
targeted areas and, for this reason or because of the
challenges of mapping short reads to the human genome, a
small portion of targets (4 to 6%) was not sufficiently
covered by sequence reads for variant calling. This aspect
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achieved with modifications to capture as well as other steps.
However, given the number of target genes analyzed and the
lack of clinical testing, our initial results are highly
encouraging. While it is ideal to achieve coverage for all the
targeted regions, this may not be realistic as some regions
may be refractory to capture, amplification or sequencing.
We plan to expand the target pool to include additional
known and candidate genes [9] and also to test the
performance of other capture systems [16,46].
A final consideration concerns the applicability of the
technique in a clinical setting based on ease of workflow and
economic aspects. The sample preparation and set-up of the
sequencing runs, while requiring expert handling, is fairly
straightforward. Only one sequencing lane was utilized per
sample and up to eight samples can be analyzed in one run.
Several aspects of the procedure are rapidly improving,
allowing increases in sequence output, sample multiplexing,
and better data analysis, which will certainly enable a cost-
effective approach to the diagnosis of several complex
genetic diseases.
C Co on nc cl lu us si io on ns s
Our data demonstrate that the use of next-generation sequen-
cing holds great promise as a tool for screening mitochondrial
disorders in patients. The availability of a diagnostic test will
provide opportunities to identify patients early in life, eliminate
lengthy and often invasive procedures, and provide life-saving
therapies, permitting prompt management and accurate
genetic counseling. Furthermore, the ability to diagnose
patients will stimulate the development of new targeted
therapies based on the known genetic defect. We expect that
the analysis of samples from patients with uncharacterized
molecular defects will allow the discovery of novel mutations in
the targeted candidate genes, thus expanding and redefining
the spectrum of mitochondrial disorders.
A Ab bb br re ev vi ia at ti io on ns s
CCDS = Consensus CDS; mtDNA, mitochondrial DNA.
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